Professor Gary Middleton

Gary Middleton is Professor of Medical Oncology in the University of Birmingham’s Institute of Immunology and Immunotherapy, Honorary Consultant Oncologist at University Hospitals Birmingham and Director of the Birmingham Experimental Cancer Medicine Centre (ECMC). He drives the translation of Birmingham cancer immunology and genomics science into novel clinical research, collaboratively delivered across the ECMC network.

A leader in Precision Medicine oncology, Gary is investigating how the genomic, transcriptomic and immunological context of cancers impacts on response to targeted therapy. Gary’s immunology research focuses on the dynamics and importance of MHC class II expression in colorectal cancer and defining predictive biomarkers for toxicity from checkpoint blockade therapy, seeking to translate findings into novel immunotherapy studies.

Find out more about Professor Gary Middleton